Pritelivir - Asahi Kasei Therapeutics
Alternative Names: AIC-316; BAY 57-1293; HOVILPRILatest Information Update: 13 Oct 2026
At a glance
- Originator Bayer
- Developer AiCuris; Asahi Kasei Therapeutics
- Class Acetamides; Amides; Antivirals; Benzyl compounds; Pyridines; Small molecules; Sulfonamides; Thiazoles
- Mechanism of Action DNA helicase-primase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Herpes simplex virus infections
- Discontinued Herpes labialis
Most Recent Events
- 13 Oct 2026 Discontinued - Phase-II for Herpes labialis in USA (Topical) (AiCuris Pipeline, October 2026)
- 09 Oct 2026 Efficacy and adverse event data from phase III PRIOH-1 trial in Herpes simplex virus infections released by AiCuris
- 09 Oct 2026 Registered for Herpes simplex virus infections (Treatment-resistant) in USA (PO) - First global approval